12 research outputs found
Hsp72 (HSPA1A) Prevents Human Islet Amyloid Polypeptide Aggregation and Toxicity: A New Approach for Type 2 Diabetes Treatment
Type 2 diabetes is a growing public health concern and accounts for approximately 90% of all the cases of diabetes. Besides insulin resistance, type 2 diabetes is characterized by a deficit in β-cell mass as a result of misfolded human islet amyloid polypeptide (h-IAPP) which forms toxic aggregates that destroy pancreatic β-cells. Heat shock proteins (HSP) play an important role in combating the unwanted self-association of unfolded proteins. We hypothesized that Hsp72 (HSPA1A) prevents h-IAPP aggregation and toxicity. In this study, we demonstrated that thermal stress significantly up-regulates the intracellular expression of Hsp72, and prevents h-IAPP toxicity against pancreatic β-cells. Moreover, Hsp72 (HSPA1A) overexpression in pancreatic β-cells ameliorates h-IAPP toxicity. To test the hypothesis that Hsp72 (HSPA1A) prevents aggregation and fibril formation, we established a novel C. elegans model that expresses the highly amyloidogenic human pro-IAPP (h-proIAPP) that is implicated in amyloid formation and β-cell toxicity. We demonstrated that h-proIAPP expression in body-wall muscles, pharynx and neurons adversely affects C. elegans development. In addition, we demonstrated that h-proIAPP forms insoluble aggregates and that the co-expression of h-Hsp72 in our h-proIAPP C. elegans model, increases h-proIAPP solubility. Furthermore, treatment of transgenic h-proIAPP C. elegans with ADAPT-232, known to induce the expression and release of Hsp72 (HSPA1A), significantly improved the growth retardation phenotype of transgenic worms. Taken together, this study identifies Hsp72 (HSPA1A) as a potential treatment to prevent β-cell mass decline in type 2 diabetic patients and establishes for the first time a novel in vivo model that can be used to select compounds that attenuate h-proIAPP aggregation and toxicity
Serum Vitamin B12 and thyroid hormone levels in Saudi patients with multiple sclerosis
Objectives: To determine the relationship between Vitamin B12 levels and thyroid hormones in patients with multiple sclerosis (MS). Materials and Methods: One hundred and ten patients with MS were recruited for this study after Institutional Review Board approval. All patients signed a written informed consent form and donated a single blood sample. Plasma Vitamin B12 levels, triiodothyronine (T3), and thyroxine (T4) hormone levels were measured. Data were analyzed using the Statistical Package for Social Sciences (SPSS) software. Results: Analysis of Vitamin B12 levels in 110 patients with MS revealed that 65% had normal levels of Vitamin B12 (200-900 pg/ml), 30% had low levels of Vitamin B12 (<200 pg/ml), and 5% high levels of Vitamin B12 (higher than 900 pg/ml). Further analysis of patients with low levels of Vitamin B12 revealed that this cohort exhibited a significantly high number of patients with low levels of the thyroid hormones triiodothyronine (T3) and thyroxine (T4) (P < 0.005). Conclusion: This study suggests a relationship between Vitamin B12 levels and thyroid hormones. This opens the possibility that the use of therapies that increase triiodothyronine (T3) and thyroxine (T4) levels might be beneficial to patients with MS
Psychometric properties of an Arabic version of the fatigue severity scale in patients with stroke
Hsp72 expression improves the solubility of h-proIAPP aggregates.
<p><b>A.</b> Transgenic YFP + Hsp72 <i>C</i>. <i>elegans</i> model was generated by co-injection of 20 ng/μl of plasmid pPR18 (that expresses YFP in muscles) together with 30 ng/μl of Hsp72 expressed in the same tissue (plasmid pPR21) to serve as a soluble control (top panels). <i>C</i>. <i>elegans</i> injected with 20 ng/μl of h-proIAPP tagged with YFP expressed in muscles (plasmid pPR3) was used as a control for protein aggregation (middle panels). Transgenic h-proIAPP::YFP + Hsp72 <i>C</i>. <i>elegans</i> animals were generated by gonad co-injection of 20 ng/μl of plasmid pPR3 and 30 ng/μl of plasmid pPR21 (bottom panels). Transgenic animals were subjected to FRAP analysis (square). Data was collected before photobleaching (left panels), 10 seconds after photobleaching (middle panels) and 250 seconds after photobleaching (right panels). Images were obtained using an inverted confocal microscope. Results are representative of one experiment from at least three independently performed experiments with similar results. Scale bars represent 50 μm. <b>B.</b> Data represents the quantification of relative fluorescence intensity, RFI ± SEM during recovery after photobleaching of transgenic h-proIAPP::YFP <i>C</i>. <i>elegans</i> model (filled circles), transgenic h-proIAPP::YFP + Hsp72 <i>C</i>. <i>elegans</i> animals (open circles), and transgenic YFP + Hsp72 <i>C</i>. <i>elegans</i> model (filled triangles). Data are the mean of at least three independently performed experiments. *p<0.05 versus h-proIAPP::YFP, Error Bar = SEM.</p
Expression of h-proIAPP in <i>C</i>. <i>elegans</i> results in protein insolubility and aggregation.
<p>Transgenic h-proIAPP <i>C</i>. <i>elegans</i> model was generated by gonad microinjection of 20 ng/μl of plasmids pPR3, pPR4 and pPR5. Transgenic m-proIAPP <i>C</i>. <i>elegans</i> model was generated by gonad microinjection of 20 ng/μl of plasmids pPR8, pPR9 and pPR10. <b>A.</b> h-proIAPP and m-proIAPP tagged with YFP were expressed in body wall muscles, vulva muscles and anal depressor muscles under <i>lev-11</i> promoter; in pharynx under <i>tnt-4</i> promoter, and in neurons under <i>aex-3</i> promoter. Neuronal expression of proIAPP secreted into the body cavity was observed in the coelomocytes of the h-proIAPP model and distributed in the intestinal region in both h-proIAPP and m-proIAPP <i>C</i>. <i>elegans</i> models. Images were created using maximum intensity projections on all the planes of the acquired stacks except coelomocytes where images were taken in a single plane for better visualization. Arrows indicate areas of fluorescence. DIC images were taken to visualize structures. Results are a representative experiment from at least three independently performed experiments with similar results. Scale bars represent 50 μm. <b>B.</b> Data represent the mean fluorescence intensity (MFI) ± SD measured using a sum intensity projection on all the planes of the acquired stacks of m-proIAPP (open bars) and h-proIAPP (filled bars) tagged with YFP expressed in body wall muscles, vulva muscles, anal depressor muscles and pharynx. *p<0.05; **p<0.01 versus m-proIAPP. <b>C.</b> Transgenic h-proIAPP <i>C</i>. <i>elegans</i> tagged with YFP were subjected to FRAP analysis (square). Data are from vulva muscles (row 1), anal depressor (row 2), pharynx (row 3) and coelomocytes (row 4) before FRAP (left panels), 10 seconds after FRAP (middle panels) 250 seconds after FRAP (right panels). Images were obtained using an inverted confocal microscope. Results are representative experiment from at least three independently performed experiments with similar results. Scale bars represent 50 μm.</p
Construction and identification of human and mouse proIAPP <i>C</i>. <i>elegans</i> vectors.
<p><b>A.</b> Schematic representation of human-proIAPP and mouse-proIAPP tissue-specific vector constructs. cDNA of human and mouse proIAPP with human and mouse signal peptide, respectively, were cloned into the BamH1 restriction site of the pSX95.77YFP <i>C</i>.<i>elegans</i> vector to generate human and mouse pSX95.77YFP-proIAPP transgenes. Resulting constructs were digested with Sal1, blunt-ended and ligated into Gateway Cassette C.1 upstream of human and mouse coding sequences to create vectors pNG1 and pNG2. Destination vectors pNG1 and pNG2 were LR recombined with pLR22, pLR25 and pLR35 entry clones to generate human proIAPP plasmids: pPR3, pPR4 and pPR5 and mouse proIAPP plasmids: pPR8, pPR9 and pPR10. <b>B.</b> h-proIAPP sequence of construct pSX95.77YFP-prohIAPP with human signal peptide. Preproh-IAPP (1–89) peptide amino acid sequence is shown in black italics. Signal peptide sequence is shown in red. <b>C.</b> m-proIAPP sequence present in construct pSX95.77YFP-promIAPP with mouse signal peptide. Preprom-IAPP peptide amino acid sequence is shown in black italics. Signal peptide sequence is shown in red. Restriction sites used in the generation of these plasmids are underlined. No stop codon was included after each proIAPP sequence.</p
Expression of h-proIAPP in <i>C</i>. <i>elegans</i> correlates with growth retardation phenotype.
<p>Developmental phenotype was studied in transgenic h-proIAPP <i>C</i>. <i>elegans</i> model, transgenic m-proIAPP <i>C</i>. <i>elegans</i> model and pBX1 control animals by quantifying the number of animals in the larvae 1 (L1) to larvae 3 (L3) stages (open bars) versus larvae 4 (L4) and adult stages (filled bars) seventy-two hours after ten to fifteen gravid hermaphrodites were treated with bleach to release eggs. Data represent the percentage of animals found at larvae 1 to larvae 3 stages and the percentage of animals found at larvae 4 and adult stages ± S.D. p<0.05 versus respective control, n = 3.</p
Hsp72 reduces endogenous h-IAPP toxicity in pancreatic β-cells.
<p><b>A.</b> Beta-TC-6 cells were transfected and cell viability was assessed by MTS assay. Data represent percentage of live cells ± SD (filled bars) when transfected with vector pCMV6-XL5 (control) or human Hsp72::EGFP cDNA clone or m-proIAPP cDNA clone or h-proIAPP cDNA clone or both h-proIAPP and human Hsp72::EGFP vectors. Data represents the sum of three independently performed experiments. **p<0.01 versus respective controls, n = 3. <b>B.</b> At the end of the transfection period, phase contrast and fluorescence images were obtained. Data is a representative experiment from at least three independently performed experiments with similar results. Scale bars represent 50 μm. <b>C.</b> Beta-TC-6 cells were transfected with empty vector pCMV6-XL5 (control), or m-proIAPP cDNA clone or h-proIAPP cDNA clone or with both h-proIAPP and human Hsp72::EGFP vectors. After transfection, samples were collected and examined for the expression of h-IAPP by Western blot analysis. Data is a representative experiment from at least three independently performed experiments with similar results. <b>D.</b> Beta-TC-6 cells were transfected with empty vector pCMV6-XL5 (control), or human Hsp72::EGFP cDNA clone, or with both h-proIAPP and human Hsp72::EGFP vectors. After transfection, samples were collected and examined for the expression of Hsp72 by Western blot analysis. Data is a representative experiment from at least three independently performed experiments with similar results.</p